Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma

PURPOSE: We hypothesize that the addition of the phosphodiesterase-5 inhibitor tadalafil to the PD-1 inhibitor nivolumab, is safe and will augment immune-mediated antitumor responses in previously untreated squamous cell carcinoma of the head and neck (HNSCC). PATIENTS AND METHODS: We conducted a tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Luginbuhl, Adam J., Johnson, Jennifer M., Harshyne, Larry A., Linnenbach, Alban J., Shukla, Sanket K., Alnemri, Angela, Kumar, Gaurav, Cognetti, David M., Curry, Joseph M., Kotlov, Nikita, Antysheva, Zoya, Degryse, Sandrine, Mannion, Kyle, Gibson, Michael K., Netterville, James, Brown, Brandee, Axelrod, Rita, Zinner, Ralph, Tuluc, Madalina, Gargano, Stacey, Leiby, Benjamin E., Shimada, Ayako, Mahoney, My G., Martinez-Outschoorn, Ubaldo, Rodeck, Ulrich, Kim, Young J., South, Andrew P., Argiris, Athanassios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898272/
https://www.ncbi.nlm.nih.gov/pubmed/34911681
http://dx.doi.org/10.1158/1078-0432.CCR-21-1816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898272/
https://www.ncbi.nlm.nih.gov/pubmed/34911681
http://dx.doi.org/10.1158/1078-0432.CCR-21-1816

Ejemplares similares